Top

Published in:

01-12-2024 | Review

Statin-Associated Muscle Symptoms: Identification and Recommendations for Management

Authors: Kevin C. Maki, Carol F. Kirkpatrick, Mary Katherine Cheeley, Terry A. Jacobson

Published in: Current Atherosclerosis Reports | Issue 1/2024

Abstract

Purpose of Review

Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and management of patients with SAMS.

Recent Findings

The National Lipid Association and other professional societies have issued guidance to assist clinicians in identifying and managing patients with partial or complete statin intolerance. The most common reason for intolerance is SAMS. This review discusses strategies to achieve therapeutic objectives for atherogenic lipoprotein management in patients with SAMS.

Summary

Many patients who experience SAMS can tolerate some degree of statin therapy and non-statin medications are available as adjunctive or alternative treatments. With a thorough clinician-patient discussion and shared decision-making, a treatment plan can be identified to achieve therapeutic objectives and reduce the risk of atherosclerotic cardiovascular disease.

Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5.CrossRef

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. https://doi.org/10.1093/eurheartj/ehx144.CrossRefPubMedPubMedCentral

Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a Consensus Statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313–30. https://doi.org/10.1093/eurheartj/ehz962.CrossRefPubMedPubMedCentral

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA, /ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350. https://doi.org/10.1016/j.jacc.2018.11.003

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.CrossRefPubMed

Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129–50. https://doi.org/10.1016/j.cjca.2021.03.016.CrossRefPubMed

Soffer DE, Marston NA, Maki KC, Jacobson TA, Bittner VA, Pena JM, et al. Role of apolipoprotein B in the Clinical Management of Cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024. https://doi.org/10.1016/j.jacl.2024.08.013.CrossRefPubMed

Cholesterol Treatment Trialists C. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832–45. https://doi.org/10.1016/S0140-6736(22)01545-8.CrossRef

Iatan I, Mancini GBJ, Yeoh E, Hegele RA. Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management. Expert Rev Cardiovasc Ther. 2023;21(6):423–35. https://doi.org/10.1080/14779072.2023.2215982.CrossRefPubMed

10.

Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410. https://doi.org/10.1016/j.jacc.2016.02.071.CrossRefPubMed

11.

Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, et al. NLA Scientific Statement on Statin Intolerance: a New Definition and Key Considerations for ASCVD Risk Reduction in the Statin Intolerant Patient. J Clin Lipidol. 2022;16(4):361–75. https://doi.org/10.1016/j.jacl.2022.05.068CrossRefPubMed

12.

Toth PP, Granowitz C, Hull M, Anderson A, Philip S. Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. Lipids Health Dis. 2019;18(1):175. https://doi.org/10.1186/s12944-019-1099-z.CrossRefPubMedPubMedCentral

13.

Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. https://doi.org/10.1016/j.jacl.2012.03.003CrossRefPubMed

14.

Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1–23. https://doi.org/10.5114/aoms.2015.49807.CrossRefPubMedPubMedCentral

15.

Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012–22. https://doi.org/10.1093/eurheartj/ehv043.CrossRefPubMedPubMedCentral

16.

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81. https://doi.org/10.1161/ATV.0000000000000073.

17.

Zhang H, Plutzky J, Shubina M, Turchin A. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann Intern Med. 2017;167(4):221–7. https://doi.org/10.7326/M16-0838.CrossRefPubMed

18.

Warden BA, Guyton JR, Kovacs AC, Durham JA, Jones LK, Dixon DL, et al. assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the national lipid association. J Clin Lipidol. 2023;17(1):19–39. https://doi.org/10.1016/j.jacl.2022.09.001.CrossRefPubMed

19.

Guyton JR, Bays HE, Grundy SM, Jacobson TA, The national lipid association statin intolerance P. an assessment by the statin intolerance panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72–81. https://doi.org/10.1016/j.jacl.2014.03.002CrossRefPubMed

20.

Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016). Can J Cardiol. 2016;32(7 Suppl):S35–65. https://doi.org/10.1016/j.cjca.2016.01.003.CrossRefPubMed

21.

Sposito AC, Faria Neto JR, Carvalho LS, Lorenzatti A, Cafferata A, Elikir G, et al. Statin-associated muscle symptoms: position paper from the luso-latin American consortium. Curr Med Res Opin. 2017;33(2):239–51. https://doi.org/10.1080/03007995.2016.1252740.CrossRefPubMed

22.

Cheeley MK, Clegg K, Lockridge C, Schubert TJ, Jones LK. Statin intolerance: an overview of US and international guidance. Curr Atheroscler Rep. 2023;25(8):517–26. https://doi.org/10.1007/s11883-023-01124-z.CrossRefPubMedPubMedCentral

23.

Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The national lipid association’s muscle safety expert panel. an assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58–71. https://doi.org/10.1016/j.jacl.2014.03.004.CrossRefPubMed

24.

Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):C52–60. https://doi.org/10.1016/j.amjcard.2005.12.010.CrossRef

25.

Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103. https://doi.org/10.1161/CIRCULATIONAHA.112.136101.CrossRefPubMed

26.

Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–90. https://doi.org/10.1001/jama.2016.3608.CrossRefPubMed

27.

Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758–69. https://doi.org/10.1016/j.jacl.2015.08.006.CrossRefPubMed

28.

Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. https://doi.org/10.1136/bmj.n135.CrossRefPubMedPubMedCentral

29.

Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78(12):1210–22. https://doi.org/10.1016/j.jacc.2021.07.022.CrossRefPubMedPubMedCentral

30.

Karalis DG, Wild RA, Maki KC, Gaskins R, Jacobson TA, Sponseller CA, et al. Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. J Clin Lipidol. 2016;10(4):833–41. https://doi.org/10.1016/j.jacl.2016.02.016.CrossRefPubMed

31.

Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the Use of Statins in America and Gaps in Patient Education. J Clin Lipidol. 2013;7(5):472–83. https://doi.org/10.1016/j.jacl.2013.03.001.CrossRefPubMed

32.

Jacobson TA, Cheeley MK, Jones PH, La Forge R, Maki KC, Lopez JAG, et al. The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415–24. https://doi.org/10.1016/j.jacl.2019.04.011.CrossRefPubMed

33.

Stock JK. Update on SAMS: statin-associated muscle symptoms. Atherosclerosis. 2018;269:260–1. https://doi.org/10.1016/j.atherosclerosis.2017.12.032.CrossRefPubMed

34.

Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, Nanna MG, et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol. 2022;79(18):1802–13. https://doi.org/10.1016/j.jacc.2022.02.048.CrossRefPubMedPubMedCentral

35.

Zheutlin AR, Derington CG, Herrick JS, Rosenson RS, Poudel B, Safford MM, et al. Lipid-lowering therapy use and intensification among United States veterans following myocardial infarction or coronary revascularization between 2015 and 2019. Circ Cardiovasc Qual Outcomes. 2022;15(12):e008861. https://doi.org/10.1161/CIRCOUTCOMES.121.008861.CrossRefPubMedPubMedCentral

36.

Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060–8. https://doi.org/10.1001/jamacardio.2021.1810.CrossRefPubMed

37.

Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279–89. https://doi.org/10.1093/eurjpc/zwaa047.CrossRefPubMed

38.

Dixon DL, Sharma G, Sandesara PB, Yang E, Braun LT, Mensah GA, et al. Therapeutic inertia in cardiovascular disease prevention: time to move the bar. J Am Coll Cardiol. 2019;74(13):1728–31. https://doi.org/10.1016/j.jacc.2019.08.014CrossRefPubMed

39.

Virani SS, Ballantyne CM, Petersen LA. Guideline-concordant statin therapy use in secondary prevention: should the medical community wait for divine intervention? J Am Coll Cardiol. 2022;79(18):1814–7. https://doi.org/10.1016/j.jacc.2022.02.042CrossRefPubMed

40.

Usherwood T. Therapeutic inertia. Aust Prescr. 2024;47(1):15–9. https://doi.org/10.18773/austprescr.2024.001.CrossRefPubMedPubMedCentral

41.

Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179–86. https://doi.org/10.1007/s10557-017-6723-4.CrossRefPubMedPubMedCentral

42.

American College of Cardiology. ACC Statin Intolerance App. https://www.acc.org/statinintoleranceapp (2024). Accessed September 12, 2024 2024.

43.

Dulay D, LaHaye SA, Lahey KA, Day AG. Efficacy of alternate day versus daily dosing of rosuvastatin. Can J Cardiol. 2009;25(2):e28–31. https://doi.org/10.1016/s0828-282x(09)70480-5.CrossRefPubMedPubMedCentral

44.

Kennedy SP, Barnas GP, Schmidt MJ, Glisczinski MS, Paniagua AC. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J Clin Lipidol. 2011;5(4):308–15. https://doi.org/10.1016/j.jacl.2011.03.454.CrossRefPubMed

45.

Pattanaik S, Malhotra S, Sharma YP, Pandhi P. Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile. J Cardiovasc Pharmacol. 2012;59(5):479–84. https://doi.org/10.1097/FJC.0b013e31824ba699.CrossRefPubMed

46.

Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. The high-dose rosuvastatin once weekly study (the HD-ROWS). J Clin Lipidol. 2012;6(4):362–7. https://doi.org/10.1016/j.jacl.2011.11.002.CrossRefPubMed

47.

Sadowska A, Osinski P, Roztocka A, Kaczmarz-Chojnacka K, Zapora E, Sawicka D, et al. Statins-from fungi to pharmacy. Int J Mol Sci. 2024;25(1):466. https://doi.org/10.3390/ijms25010466.CrossRef

48.

Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366–418. https://doi.org/10.1016/j.jacc.2022.07.006.CrossRef

49.

Pogran E, Burger AL, Zweiker D, Kaufmann CC, Muthspiel M, Rega-Kaun G, et al. Lipid-lowering therapy after acute coronary syndrome. J Clin Med. 2024;13(7). https://doi.org/10.3390/jcm13072043.

50.

Biccire FG, Kakizaki R, Koskinas KC, Ueki Y, Haner J, Shibutani H, et al. Lesion-level effects of LDL-C-lowering therapy in patients with acute myocardial infarction: a post hoc analysis of the PACMAN-AMI trial. JAMA Cardiol. 2024. https://doi.org/10.1001/jamacardio.2024.3200.CrossRefPubMed

51.

Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64. https://doi.org/10.1056/NEJMoa2215024.CrossRefPubMed

52.

Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023;330(2):131–40. https://doi.org/10.1001/jama.2023.9696.CrossRefPubMedPubMedCentral

53.

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351–64. https://doi.org/10.1001/jama.1984.03340270029025.CrossRef

54.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97. https://doi.org/10.1056/NEJMoa1410489.CrossRefPubMed

55.

Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation. 2019;140(12):992–1003. https://doi.org/10.1161/CIRCULATIONAHA.118.039415.CrossRefPubMed

56.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107. https://doi.org/10.1056/NEJMoa1801174.CrossRefPubMed

57.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. https://doi.org/10.1056/NEJMoa1615664.CrossRefPubMed

58.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61. https://doi.org/10.1016/S0140-6736(05)67667-2.CrossRefPubMed

59.

Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74. https://doi.org/10.1056/NEJMoa1001282.

60.

Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237–45. https://doi.org/10.1056/NEJM198711123172001.CrossRefPubMed

61.

Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410–8. https://doi.org/10.1056/NEJM199908053410604.CrossRefPubMed

62.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.CrossRefPubMed

Title: Statin-Associated Muscle Symptoms: Identification and Recommendations for Management
Authors: Kevin C. Maki
Carol F. Kirkpatrick
Mary Katherine Cheeley
Terry A. Jacobson
Publication date: 01-12-2024
Publisher: Springer US
Published in: Current Atherosclerosis Reports / Issue 1/2024
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-024-01246-y

Bridging the Gap: How Accounting for Social Determinants of Health Can Improve Digital Health Equity in Cardiovascular Medicine

Digital Health
Review

Do statins affect cognitive health?

Open Access
Statins
Review

Statin Therapy for Primary and Secondary Prevention in Older Adults

Open Access
Pravastatin
Review

Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion

Arterial Occlusive Disease
Review

The Role of Iron in Atherosclerosis and its Association with Related Diseases

Arterial Occlusive Disease
Review

Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease

Hypercholesterolemia
Review

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content